MCL-1 as the Central Venetoclax Resistance Node

MCL-1 (myeloid cell leukemia-1) overexpression is the single most recurrently cited mechanism of venetoclax resistance across more than 15 retrieved research results spanning AML, multiple myeloma (MM), mantle cell lymphoma (MCL), and DLBCL. As the Amsterdam UMC review confirms, “decreased sensitivity [to venetoclax] is associated with upregulation of MCL-1” — a finding replicated by independent groups at the Mayo Clinic, MD Anderson Cancer Center, and the University Hospital Bern. The Mayo Clinic characterises MCL-1 as “one of the most frequently amplified genes in cancer” and a driver of venetoclax resistance across hematologic tumors.

The biological rationale is straightforward: venetoclax is a selective BCL-2 BH3-mimetic that displaces pro-apoptotic proteins from BCL-2. When MCL-1 is overexpressed, it sequesters those same pro-apoptotic proteins — BIM, NOXA, PUMA — redirecting apoptotic signalling away from the venetoclax-sensitive BCL-2 node. This creates a parallel survival pathway that venetoclax alone cannot address.

Disease-specific patterns of MCL-1 dependence are well-documented. In multiple myeloma, results from the University of Colorado and Emory University’s Winship Cancer Institute confirm that MCL-1 is the dominant BCL-2 family survival factor in most MM subtypes, with BCL-2 itself relevant primarily in the t(11;14) translocation subgroup. In MCL and DLBCL — including cell lines bearing the t(14;18) translocation — co-expression of MCL-1 alongside BCL-2 is identified as the principal driver of intrinsic and acquired venetoclax resistance. A 2012 study from the University of Magdeburg documented selective MCL-1 upregulation in FLT3-ITD-positive AML cell lines and primary blasts, showing that reversal of this upregulation via FLT3 inhibition restored sensitivity to cytotoxic agents — establishing the upstream signalling link that later kinase inhibitor combination strategies would exploit.

Direct BH3-Mimetic MCL-1 Inhibitors: Agents and Evidence

Direct MCL-1 inhibitors occupy the BH3-binding groove of the MCL-1 protein, preventing it from sequestering pro-apoptotic effectors — the most mechanistically targeted approach to overcoming MCL-1-driven venetoclax resistance. Four named agents with preclinical activity are documented in the retrieved literature, all at predominantly preclinical development stages.

S63845 is the most broadly evaluated direct MCL-1 inhibitor in this dataset. The University Hospital Bern tested it in combination with MDM2 inhibitor HDM201 and MEK1/2 inhibitor trametinib in AML models in 2019. Yale University (2020) demonstrated single-agent S63845 activity across all MDS subtypes — in contrast to venetoclax, whose activity correlated with blast count — and validated dual BCL-2/MCL-1 inhibition using S63845 plus venetoclax in MISTRG6 mouse models.

AMG-176 was evaluated by the University of Modena (2022) in venetoclax-resistant CLL cells with trisomy 12, where Notch2-induced MCL-1 upregulation conferred resistance. Adding AMG-176 to venetoclax overcame this Notch2/MCL-1-mediated resistance, validating the Notch2–MCL-1 axis as a tractable combination target in B-cell malignancies. A-1210477, studied by AbbVie (2015) in NHL and DLBCL cell lines bearing the t(14;18) translocation, demonstrated that loss of MCL-1 function sensitised BCL2-high cells to venetoclax, identifying MCL-1 and BCL-2 as the two co-essential survival targets in this lymphoma subtype.

KS18, a pyoluteorin-derived MCL-1 inhibitor characterised by Cooper Health University in 2023, adds a mechanistic dimension absent from earlier agents: it promotes ubiquitin-proteasome system (UPS)-dependent MCL-1 degradation rather than simple BH3-groove occupancy. This degradation mechanism sensitised bortezomib- and venetoclax-resistant multiple myeloma cells, suggesting potential utility in heavily pre-treated MM patients who have progressed past proteasome inhibitor lines — a population with limited options according to NIH-supported myeloma research programmes.

“Novel MCL-1 inhibitors are under clinical investigation” — Mayo Clinic, 2019; yet no Phase III trial results specifically evaluating a direct MCL-1 inhibitor were found in the retrieved dataset, underscoring the translational gap that the field must still close.

The CDK9–MCL-1 Transcriptional Axis and Indirect Suppression Strategies

CDK9 inhibition is the most extensively represented indirect MCL-1 suppression strategy in the retrieved dataset, with converging evidence from Temple University, Cleveland Clinic, and Monash University’s Blood Cancer Therapeutics Laboratory. CDK9 is the catalytic subunit of P-TEFb, which phosphorylates RNA Polymerase II at Serine 2 to drive transcriptional elongation of short-lived survival genes including MCL-1 and MYC. Because MCL-1 protein has a short half-life, CDK9 inhibition causes rapid but transient loss of MCL-1 — a pharmacological characteristic that shapes the entire clinical development strategy for this drug class.

Voruciclib is the most clinically proximate CDK9 inhibitor in this dataset for AML. Research from the First Hospital of Jilin University (2020) demonstrated synergistic antileukemic activity when voruciclib was combined with venetoclax in AML cell lines and primary patient samples via MCL-1 and c-Myc downregulation. Critically, the transient nature of MCL-1 suppression upon CDK9 inhibition necessitated an intermittent, every-other-day dosing schedule to achieve durable efficacy — a key parameter for IND design and clinical scheduling. A-1592668, an orally active CDK9 inhibitor developed through collaboration between AbbVie and Monash University (2019), demonstrated a distinct selectivity profile with potent downregulation of RNA Pol-II Ser2 phosphorylation and MCL-1, inducing apoptosis in MCL-1-dependent hematologic cell lines.

Earlier CDK inhibitors with documented MCL-1 suppression activity include flavopiridol (AbbVie, 2015 — shown to synergise with venetoclax in BCL2-high NHL cell lines) and dinaciclib (Peter MacCallum Cancer Centre, 2014 — demonstrated potent MCL-1 suppression and durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo). CDK7 inhibition represents an adjacent strategy: QS1189, a novel CDK7 inhibitor studied at Asan Medical Center (2019), overcomes acquired venetoclax resistance in MCL by suppressing RNA Pol-II phosphorylation and transcriptional output, implicating CDK7 alongside CDK9 as a viable transcriptional target.

A mechanistically distinct CDK-based approach comes from a 2022 EMBL Heidelberg paper on CDK7/12/13 inhibition in AML stem cells, which demonstrated synergy with venetoclax through targeting an oscillating leukemia stem cell (LSC) network — a rationale that extends beyond MCL-1 suppression alone and implicates the broader transcriptional CDK family in LSC-level resistance. CDK9 inhibition has also been identified as a vulnerability in ibrutinib-resistant MCL, where enhancer remodelling drives transcriptional addiction susceptible to CDK9 blockade (Moffitt Cancer Center, 2021), broadening the clinical context for this strategy beyond venetoclax resistance alone. According to NCI, transcriptional CDK inhibitors represent one of the most active areas of investigation in lymphoma biology.

NOXA Induction and Radioimmunotherapy: Alternative Routes to MCL-1 Neutralisation

Two mechanistically distinct strategies for neutralising MCL-1 without direct protein-binding inhibitors have generated notable preclinical evidence: pharmacological induction of the endogenous MCL-1 antagonist NOXA, and DNA-damage-triggered MCL-1 degradation via radioimmunotherapy.

NOXA Induction via Pevonedistat and Auranofin

NOXA (encoded by PMAIP1) is a BH3-only protein that selectively antagonises MCL-1 by occupying its BH3-binding groove — functionally mimicking what a direct MCL-1 inhibitor would achieve, but through endogenous induction rather than exogenous small-molecule binding. Vanderbilt University (2021) demonstrated that the NEDD8-activating enzyme inhibitor pevonedistat combined with azacitidine upregulates NOXA/PMAIP1 to a greater degree than azacitidine alone, sensitising AML cells to venetoclax. This provides a mechanistic rationale for a pevonedistat/azacitidine/venetoclax triplet that could specifically overcome MCL-1-mediated resistance without requiring a direct MCL-1 inhibitor — potentially a lower-toxicity route to the same therapeutic end.

Auranofin, a thioredoxin reductase inhibitor, provides a complementary NOXA-induction mechanism. In MLL-rearranged B-cell ALL, the Medical University of Warsaw (2022) showed that auranofin induces NOXA in a p53-independent manner, sensitising to venetoclax by overcoming MCL-1-dependent resistance. The p53-independence is clinically significant: TP53 mutations are common in relapsed haematological malignancies and would render p53-dependent apoptotic pathways non-functional, as documented in ASCO-published clinical series.

Radioimmunotherapy: 225Ac-Lintuzumab and DNA-Damage-Mediated MCL-1 Degradation

225Ac-lintuzumab — an actinium-225-labelled anti-CD33 antibody developed by Actinium Pharmaceuticals in collaboration with the University of Saskatchewan — represents a mechanistically orthogonal approach. Rather than targeting MCL-1 transcription or protein binding, this clinical-stage radioimmunotherapy suppresses MCL-1 levels via DNA damage, triggering post-translational MCL-1 degradation and reversing venetoclax resistance in two preclinical AML models (2020). The agent is described as a “clinical stage radioimmunotherapy” with evidence of single-agent activity in relapsed/refractory AML, though its MCL-1-suppressing activity has been characterised only in preclinical models. According to WIPO patent filings, targeted radionuclide therapy combined with apoptosis pathway modulators represents an active area of IP development in oncology.

Combination Frameworks and Biomarker-Guided Patient Selection

Across the retrieved dataset, a multi-pronged combinatorial framework is emerging to address MCL-1-driven venetoclax resistance — with the most advanced signals pointing towards genotype-matched kinase inhibitor combinations, dual or triple BCL-2 family blockade, and flow cytometry-based biomarker stratification at the leukemia stem cell level.

Kinase Inhibitor Combinations Targeting MCL-1 Upstream

The AXL/MERTK inhibitor ONO-7475, studied at MD Anderson Cancer Center (2021), kills FLT3-ITD AML cells by targeting the ERK–MCL-1 axis downstream of FLT3, synergises potently with venetoclax, and is effective against venetoclax-resistant cells overexpressing MCL-1. This represents a genotype-matched strategy for a defined AML subgroup — an approach consistent with the broader precision oncology paradigm endorsed by FDA biomarker guidance for oncology drug development. The PI3K inhibitor bimiralisib was evaluated in combination with venetoclax, BCL-XL inhibitor A1331852, and MCL-1 inhibitors in IDH2- and FLT3-mutated AML at the University Hospital Bern (2022), signalling a potential triple BCL-2 family blockade approach in genetically defined AML subgroups.

A CRISPR-Cas9 kinome screen at Cancer Center Amsterdam (LYMMCARE, 2022) identified casein kinase 2 (CK2) as a regulator of MCL-1 stability in MCL — a novel kinase target not previously linked to MCL-1. The CK2 inhibitor silmitasertib synergises with venetoclax by downregulating MCL-1, and given shared BCL-2 family dysregulation in MCL and DLBCL, this axis may have broader implications across B-cell lymphoma subtypes.

BCL-XL as a Co-Resistance Factor Requiring Dual Targeting

Results from the University Hospital Bern and others identify BCL-XL co-upregulation as an additional escape mechanism in venetoclax-resistant disease. This finding suggests that single-agent MCL-1 inhibition may be insufficient in some disease contexts and that dual MCL-1/BCL-XL or MCL-1/BCL-2 inhibition — or even triple BCL-2 family blockade — may be required for durable responses. The retrieved dataset includes evaluation of simultaneous BCL-XL inhibitor (A1331852) plus MCL-1 inhibitor plus venetoclax in IDH2/FLT3-mutated AML, representing the most aggressive combination signal in this dataset.

The MAC-Score: Biomarker-Guided MCL-1 Targeting

A 2023 Heidelberg/HI-STEM paper introduces the MAC-Score — a flow cytometry-based measure linking expression ratios of MCL-1 and BCL-2 family proteins in leukemia stem cell (LSC) compartments to predict response to azacitidine/venetoclax therapy. This directly implicates MCL-1 protein levels in clinical outcomes and signals that prospective quantification of BCL-2 family protein ratios at the LSC level may enable patient selection for MCL-1-targeted combination regimens. Converging biomarker signals from Amsterdam UMC (BCL-2 family protein expression biomarkers) and the Mayo Clinic (CDK9 inhibitor response biomarkers) reinforce this as both a scientific opportunity and a competitive differentiator for clinical programmes pairing MCL-1 inhibitors with venetoclax.

Patent Activity and IP Landscape Signals

Innovation activity in this dataset is predominantly literature-driven, with only 3 patent records identified among approximately 70 retrieved entries. Commercial IP is concentrated in combination strategies rather than direct MCL-1 inhibitor composition-of-matter: argenx BVBA holds Singapore and EP filings covering CD70 antibody plus venetoclax combinations for AML with LSC eradication rationale, while Novartis AG holds two pending IL-jurisdiction patents covering MDM2 inhibitors post-haematopoietic cell transplantation in AML. This sparse patent landscape suggests that the MCL-1 inhibitor IP space may be undercovered in this dataset and warrants dedicated freedom-to-operate analysis in additional jurisdictions.